Replies to post #199714 on Biotech Values

[DewDiligence]

Table of %change since latest capital raise for all 128 biotech stocks in ^NBI:

https://t.co/TfvE0NjIYM

Prepared by @bradloncar.

[DewDiligence]

2016 was bad year for biotech IPOs. Almost all biotech companies who IPOd during 2Q16 or later are currently trading below their IPO price, and those who IPOd during 1Q16 raised less money than they wanted, by and large.

A telling stat: The average proportion of insider money participating in 2016 biotech IPOs was 40%—double the average proportion during 2014-2015.

http://www.fiercebiotech.com/biotech/biotech-ipo-market-slowdown-will-it-continue-into-2017